Fredun Pharmaceuticals (539730) Q1 24/25 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter ended June 30, 2024, following a review by the Audit Committee and statutory auditors.

• Financials prepared in accordance with Ind AS and SEBI regulations, with a limited review yielding an unmodified conclusion.

Financial highlights

• Total income from operations for Q1 FY25 was ₹7,881.08 lakhs, up from ₹6,204.55 lakhs in Q1 FY24.

• Net profit for Q1 FY25 stood at ₹412.99 lakhs, compared to ₹240.17 lakhs in Q1 FY24.

• Total comprehensive income for Q1 FY25 was ₹412.99 lakhs, versus ₹240.17 lakhs in Q1 FY24.

• Basic and diluted EPS for Q1 FY25 was ₹8.79, up from ₹5.24 in Q1 FY24.

Key financial ratios and metrics

• Paid-up equity share capital as of June 30, 2024, was ₹469.92 lakhs.

• Public shareholding stood at 50.83% as of June 30, 2024.